Exchange: NYSE·Updated 07:59 PM EST
EW logo

EW Edwards Lifesciences Corp

$101.85
$2.03
(1.95%)
Today
Closed $101.85
$0.0918
(0.09%)
After Hours
Reported EarningsNov 4
Mkt Cap$58.56B
Vol3.62M

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
44

Bearish Sentiment

How do you feel about EW?

GettnFibbywIT
$EW $IHI Edwards Lifesciences (EW) - Weekly Chart Price has made a strong move to reclaim the multi-year $94-$96 resistance band and the 50% Fibonacci retracement level. The next key test lies near the psychologically important $100 area, which aligns with upper diagonal resistance, the 61.8% Fibonacci retracement, and a significant market-memory resistance zone originating from the April-May 2022 decline.
1
kcphaeton
$EW $MNKD Great to see Edwards percolating again. It’s been a long time road, perhaps. Will see it eventually get back to its all-time high from 2021 • All-Time High Context: The stock's all-time historical closing high remains $130.68, set on December 30, 2021. Average cost per share $15.73 going back to 2013 original investment. 
3
gassedprowler
$EW call highlights, 👀$AVR -In the last few quarters, we gained share and our competitive position improved. But we believe that we have reached a plateau here -Bernard Zovighian: And if you look at the big picture here, this made us very confident. It is not dependent on share gains. It is truly dependent about growing the number of patients -Bernard Zovighian: Thank you. Maybe I can start at the high level, and then Dan, again, can provide some additional comments here. What we have said over the years is that over time, 👀we can expect us losing slightly some share. More competition is coming, and we all know that. 👀So if you ask me in the next 10 years, a slight loss of share, but largely offset by what we are doing to grow the market, what we are doing to have more indication, what we are doing to get into -- to make sure the penetration of TAVR is also improving. We have been saying that for a long time, and it is going to be the same, again, largely offset.
2
MarkNewtonCMT
Many ignore stocks that haven't gone anywhere in five years, but if their bases are preceded by periods of 10X+ & they start showing relative strength, they tend to be something i "pay attention" to, like $EW Healthcare remains "the sector" in the short run, & while this period normally gives way to mean reversion into early next year, 2026 is not your typical market, nor cycle. No position for me, but find IBD's "Stocks Breaking Out" list often helpful, even if its not a breakout to ATH. #IBDPartner
1
openclassaction2
$EW the $39 million securities settlement, about $0.66 per share, suit alleges tavr growth was misstated, claims by dec 2, per open class actions. seems like growth guidance gets repriced in court too
1
openclassaction2
$EW the $39 million edwards lifesciences securities settlement is open, about $0.66 per share, claim by dec 2, per open class actions. suit alleged tavr growth was misstated. growth, alleged
openclassaction2
$EW the $39 million edwards lifesciences securities settlement is open, per open class actions. suit alleges tavr growth was misstated, about $0.66 per share est. claim by dec 2
BarkStreetmilx
Many investors overlook stocks that have gone nowhere over the past five years. But when a stock has previously delivered a 10X+ move before forming a long-term base, and is now starting to show relative strength, it's the kind of setup that gets my attention — $EW is one example. Healthcare remains the sector to watch in the near term. While this phase would normally give way to mean reversion heading into early next year, 2026 is no ordinary market year, and this is no ordinary market cycle. I don't currently have a position, but I've found IBD's "Stocks Breaking Out" list to be a useful resource — even when the breakout isn't to an all-time high (ATH).
shoc24
$EW is ranked #17 in healthcare technical trend with a score of 82. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
StocktwitsEarnings
$EW Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.80 up 19.40% YoY • Reported revenue of $1.72B up 10.53% YoY • Edwards Lifesciences expects approximately $45M of additional Pillar Two tax expense in 2026 before current-law offsets; UTPR tax expense will be reduced as countries enact the Side-by-Side Safe Harbour.

Advertisement|Remove ads.